Egyptian pharmaceutical company Mina Pharm has reported a significant turnaround to profitability in the first half of 2026, achieving a net profit after taxes of 108.5 million EGP. This marks a substantial improvement from the 211.6 million EGP in losses recorded during the same period in 2025. The company's financial performance was primarily driven by a 22.6% increase in revenues, which reached 4.096 billion EGP, compared to 3.339 billion EGP in the corresponding period of 2025.
Mina Pharm's financial statements for the six months ending June 30, 2026, revealed a slight increase in gross profit to 1.291 billion EGP, up from 1.277 billion EGP in the same period of 2025. The company's operating profit also showed a modest growth, reaching 635.8 million EGP, compared to 618.8 million EGP in the first half of 2025. These improvements reflect the company's efforts to enhance its operational efficiency and financial performance.
The company's profit before income taxes also showed a notable turnaround, reaching 167.8 million EGP in the first half of 2026, compared to losses of 84.2 million EGP in the same period of 2025. Mina Pharm's shareholders' equity also benefited from the improved performance, with the parent company's share of net profit reaching 102.2 million EGP, while non-controlling interests accounted for 6.25 million EGP.
On a per-share basis, Mina Pharm's basic and diluted earnings per share (EPS) showed a significant improvement, reaching 7.72 EGP in the first half of 2026, compared to a loss of 20.95 EGP per share in the same period of 2025. This turnaround reflects the company's successful efforts to restore profitability and improve its financial health.
Focusing on the second quarter of 2026, Mina Pharm reported a 31.5% increase in revenues, reaching 2.277 billion EGP, compared to 1.732 billion EGP in the same quarter of 2025. The company's gross profit also showed a substantial increase, reaching 697.7 million EGP, up from 298.5 million EGP in the second quarter of 2025, representing a 134% growth.
Mina Pharm's net profit after taxes for the second quarter of 2026 reached 38.6 million EGP, compared to 37.4 million EGP in the same quarter of 2025. This performance indicates that the company has maintained its momentum and continued to improve its financial results.
Overall, Mina Pharm's financial performance in the first half of 2026 demonstrates a significant improvement in profitability, driven by revenue growth and operational efficiency. The company's ability to achieve a net profit of 108.5 million EGP highlights its resilience and potential for future growth.
Key points
- Mina Pharm achieved a net profit of 108.5 million EGP in the first half of 2026.
- The company's revenue grew by 22.6% to 4.096 billion EGP in the first half of 2026.
- Mina Pharm's gross profit increased slightly to 1.291 billion EGP in the first half of 2026.
